Erasca is a clinical-stage precision oncology company focused on targeting the RAS/MAPK pathway, which is commonly mutated in various cancers.

Erasca, Inc.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

COM:ERASCA

Erasca

Last Close

1.63

14/02 21:00

Market Cap

696.38M

Beta: -

Volume Today

1.80M

Avg: -

name

homepage url

country

employee count

sector

industry

Description

competitor of

Metrics